Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Current Assets (2016 - 2025)

Adma Biologics (ADMA) has disclosed Current Assets for 14 consecutive years, with $466.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets rose 40.77% year-over-year to $466.5 million, compared with a TTM value of $466.5 million through Dec 2025, up 40.77%, and an annual FY2025 reading of $466.5 million, up 40.77% over the prior year.
  • Current Assets was $466.5 million for Q4 2025 at Adma Biologics, up from $402.7 million in the prior quarter.
  • Across five years, Current Assets topped out at $466.5 million in Q4 2025 and bottomed at $171.4 million in Q2 2021.
  • Average Current Assets over 5 years is $280.0 million, with a median of $268.3 million recorded in 2022.
  • The sharpest move saw Current Assets decreased 4.95% in 2023, then skyrocketed 40.77% in 2025.
  • Year by year, Current Assets stood at $208.7 million in 2021, then increased by 29.55% to $270.4 million in 2022, then fell by 4.95% to $257.0 million in 2023, then increased by 28.95% to $331.4 million in 2024, then surged by 40.77% to $466.5 million in 2025.
  • Business Quant data shows Current Assets for ADMA at $466.5 million in Q4 2025, $402.7 million in Q3 2025, and $399.6 million in Q2 2025.